MDNA News and Press, Medicenna Therapeutics Corp. From 04/05/21

Potential for 100 gene therapy trials to be using ClearPoint. Expect significant growth in 2H 2021 as elective surgeries rebound and clinical trials restart. Recent expansion to Europe augurs well for European biologics partners. We see potential for $100M+ revenues and 30%+ n...

-- MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model -- Preclinical data demonstrates the potential of BiSKITs TM ( Bi -functional S uper K ine I mmuno T herapie ...

The following slide deck was published by Medicenna Therapeutics Corp. in conjunction with this event. For further details see: Medicenna Therapeutics (MDNA) Investor Presentation - Slideshow

TORONTO and HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the publication of an abstract for an electronic poster that wi...

TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of th...

TORONTO and HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,&...

TORONTO and HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medice...

Medicenna Therapeutics (MDNA): FQ3 GAAP EPS of -$0.11.Cash, cash equivalents and marketable securities of $33.2M.Press Release For further details see: Medicenna Therapeutics reports FQ3 results

TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended December 31, 2020...

Medicenna Therapeutics (MDNA) has entered into a sales agreement with SVB Leerink, pursuant to which the Company may, from time to time sell, through ATM offerings on Nasdaq for an aggregate offering price of up to $25M. The Company plans to use the net proceeds of the ATM Offering, if any, f...